CLINICAL TRIALS PROFILE FOR FLIBANSERIN
✉ Email this page to a colleague
All Clinical Trials for FLIBANSERIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00277914 ↗ | Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women | Completed | Sprout Pharmaceuticals, Inc | Phase 3 | 2006-01-01 | To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment. |
| NCT00360243 ↗ | 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA | Completed | Sprout Pharmaceuticals, Inc | Phase 3 | 2006-07-01 | This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meet standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group. |
| NCT00360529 ↗ | 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder | Completed | Sprout Pharmaceuticals, Inc | Phase 3 | 2006-07-01 | This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group. |
| NCT00360555 ↗ | Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder | Completed | Sprout Pharmaceuticals, Inc | Phase 3 | 2006-07-01 | This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group. |
| NCT00441558 ↗ | A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD). | Terminated | Sprout Pharmaceuticals, Inc | Phase 3 | 2007-02-01 | To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin. |
| NCT00491829 ↗ | Flibanserin Versus Placebo in Premenopausal Women With HSDD | Completed | Sprout Pharmaceuticals, Inc | Phase 3 | 2007-06-01 | To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women. To evaluate safety and tolerability of flibanserin in such patients. |
| NCT00601367 ↗ | Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder | Completed | Sprout Pharmaceuticals, Inc | Phase 3 | 2008-01-01 | Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FLIBANSERIN
Condition Name
Clinical Trial Locations for FLIBANSERIN
Trials by Country
Clinical Trial Progress for FLIBANSERIN
Clinical Trial Phase
Clinical Trial Sponsors for FLIBANSERIN
Sponsor Name
